Biosino Bio-Technology and Science Incorporation provided unaudited consolidated earnings guidance for the year ended 31 December 2023. for the year, Group is expected to record a net loss within a range of RMB 18,000,000 to RMB 22,000,000 for the Reporting Period as compared to a net profit of approximately RMB 14,202,000 for the year ended 31 December 2022. The Board considers that the expected loss for the Reporting Period is mainly attributable to (i) a decrease in the Group's gross profit due to (a) a drop in market demand as affected by changes in public health prevention and control policies both domestically and abroad; and (b) a drop in price of products as affected by industry centralised procurement; and (ii) an increase in the Group's research and development expenses on the its advantageous products, such as flow cytometry and supporting reagents.